Abstract
In recent years, we have witnessed tremendous progress in the development of drugs to treat diabetes. Notably, the continuous refinements of glucagon-like peptide-1 (GLP-1) receptor agonists have led to a series of registered drugs, which efficiently improve glycaemia in patients with type 2 diabetes. Although effective in the management of hyperglycaemia, selective targeting at the GLP-1 receptor has finite efficacy in treatment of obesity, with dose-dependent gastrointestinal effects restricting higher doses that more effectively decrease bodyweight.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
